Sierra Oncology Inc (SRRA) Stock Overview
NASDAQ:SRRA - US82640U4040 - Common Stock
SRRA Key Statistics, Chart & Performance
The current stock price of SRRA is 54.99 null. In the past month the price increased by 0.38%. In the past year, price increased by 178.43%.
SRRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About SRRA
Company Profile
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The company is headquartered in Vancouver, British Columbia and currently employs 109 full-time employees. The company went IPO on 2015-07-16. The Company’s lead product candidate, momelotinib, which is a selective and orally bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor under investigation for the treatment of myelofibrosis. The firm is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), which is a key regulator of cell cycle progression and the DDR network. SRA141 is a bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Company Info
Sierra Oncology Inc
2150 ? 885 West Georgia Street, Suite 110
Vancouver BRITISH COLUMBIA V6C 3E8 CA
CEO: Stephen G. Dilly
Employees: 109
Phone: 16045586536.0
Sierra Oncology Inc / SRRA FAQ
What is the stock price of Sierra Oncology Inc today?
The current stock price of SRRA is 54.99 null. The price increased by 0.04% in the last trading session.
What is the ticker symbol for Sierra Oncology Inc stock?
The exchange symbol of Sierra Oncology Inc is SRRA and it is listed on the Nasdaq exchange.
On which exchange is SRRA stock listed?
SRRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Sierra Oncology Inc stock?
10 analysts have analysed SRRA and the average price target is 56.1 null. This implies a price increase of 2.02% is expected in the next year compared to the current price of 54.99. Check the Sierra Oncology Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Sierra Oncology Inc worth?
Sierra Oncology Inc (SRRA) has a market capitalization of 1.34B null. This makes SRRA a Small Cap stock.
How many employees does Sierra Oncology Inc have?
Sierra Oncology Inc (SRRA) currently has 109 employees.
What are the support and resistance levels for Sierra Oncology Inc (SRRA) stock?
Sierra Oncology Inc (SRRA) has a support level at 54.94 and a resistance level at 55. Check the full technical report for a detailed analysis of SRRA support and resistance levels.
Should I buy Sierra Oncology Inc (SRRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRRA, evaluating the profitability, health, valuation and growth aspects
- Sierra Oncology Inc (SRRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Sierra Oncology Inc (SRRA) Sales and EPS estimates to see what analysts future expectations are.
- Sierra Oncology Inc (SRRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Sierra Oncology Inc (SRRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- Sierra Oncology Inc (SRRA) Stock Chart to make your own analysis
- Sierra Oncology Inc (SRRA) Latest news and press-releases to stay up to date.
Does Sierra Oncology Inc (SRRA) stock pay dividends?
SRRA does not pay a dividend.
When does Sierra Oncology Inc (SRRA) report earnings?
Sierra Oncology Inc (SRRA) will report earnings on 2022-08-04, after the market close.
What is the Price/Earnings (PE) ratio of Sierra Oncology Inc (SRRA)?
Sierra Oncology Inc (SRRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.77).
SRRA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SRRA. When comparing the yearly performance of all stocks, SRRA is one of the better performing stocks in the market, outperforming 99.87% of all stocks.
SRRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SRRA. SRRA has a great financial health rating, but its profitability evaluates not so good.
SRRA Financial Highlights
Over the last trailing twelve months SRRA reported a non-GAAP Earnings per Share(EPS) of -6.77. The EPS decreased by -7.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.67% | ||
| ROE | N/A | ||
| Debt/Equity | 0.02 |
SRRA Forecast & Estimates
10 analysts have analysed SRRA and the average price target is 56.1 null. This implies a price increase of 2.02% is expected in the next year compared to the current price of 54.99.